Table 1.
Baseline characteristics and efficacy outcomes of all patients (N = 74)
| Variable | Mean ± standard deviation or number of patients (%) | |
|---|---|---|
| Age, years | 69.1 ± 8.8 | |
| Sex | Male | 61 (82.4) |
| Female | 13 (17.6) | |
| Smoking status | Never | 14 (18.9) |
| Former/current | 60 (81.1) | |
| Histology | Adenocarcinoma | 30 (40.5) |
| Squamous | 39 (52.7) | |
| Other* | 5 (6.8) | |
| EGFR | Wild-type | 74 (100.0) |
| Mutant | 0 (0.0) | |
| ALK rearrangement | Negative | 73 (98.6) |
| Positive | 1 (1.4) | |
| PD-L1 expression** | No (TPS < 1%) | 20 (27.1) |
| Low (TPS 1–49%) | 17 (23.0) | |
| High (TPS ≥ 50%) | 37 (50.0) | |
| Number of prior regimens | 0 | 9 (12.2) |
| 1 | 54 (73.0) | |
| ≥ 2 | 11 (14.9) | |
| Agent | Nivolumab | 16 (21.6) |
| Pembrolizumab | 31 (41.9) | |
| Atezolizumab | 27 (36.5) | |
| Best response to treatment | PR | 13 (17.6) |
| SD | 25 (33.8) | |
| PD | 36 (48.6) | |
| PseudoPD/HyperPD | Pseudoprogression | 10 (13.5) |
| Hyperprogression | 6 (8.1) | |
| Immune-related AEs | Any grade | 21 (28.4) |
| Severe AEs | 15 (20.3) |
Abbreviations: EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, PD-L1 programmed death-ligand 1, TPS tumor proportion score, PR partial response, SD stable disease, PD progression disease, PseudoPD pseudoprogression, HyperPD hyperprogression, AEs, adverse events
*One adenosquamous, one large cell, three non-small cell lung cancer not otherwise specified
**Subgroup classification according to PD-L1 expression was based on the results of the 22C3 pharmDx assay. Patients without 22C3 pharmDx assay results were classified based on the results of the SP263 assay